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The 1990 Clean Air Act Amendments list several volatile organic chemicals as hazardous air
pollutants, including ethylene oxide, butadiene, styrene, and acrylonitrile. The toxicology of many
of these compounds shares several common elements such as carcinogenicity in laboratory ani-
mals, genotoxicity of the epoxide intermediates, involvement of cytochrome P450 for metabolic
activation (except ethylene oxide), and involvement of at least two enzymes for detoxication of
the epoxides (e.g., hydrolysis or conjugation with glutathione). These similarities facilitate
research strategies for identifying and developing biomarkers of exposure. This article reviews
the current knowledge about biomarkers of butadiene. Butadiene is carcinogenic in mice and rats,
which raises concern for potential carcinogenicity in humans. Butadiene is metabolized to DNA-
reactive metabolites, including 1,2-epoxy-3-butene and diepoxybutane. These epoxides are
thought to play a critical role in butadiene carcinogenicity. Butadiene and some of its metabolites
(e.g., epoxybutene) are volatile. Exhalation of unchanged butadiene and excretion of butadiene
metabolites in urine represent major routes of elimination. Therefore, biomonitoring of butadiene
exposure could be based on chemical analysis of butadiene in exhaled breath, blood levels of
butadiene epoxides, excretion of butadiene metabolites in urine, or adducts of butadiene epoxides
with DNA or blood proteins. Mutation induction in specific genes (e.g., HPRT) following butadiene
exposure can be potentially used as a biomarker. Excretion of 1,2-dihydroxy-4-(N-acetylcysteinyl-
S)butane or the product of epoxybutene with N-7 in guanine in urine, epoxybutene-hemoglobin
adducts, and HPRT mutation have been used as biomarkers in recent studies of occupational
exposure to butadiene. Data in laboratory animals suggest that diepoxybutane may be a more
important genotoxic metabolite than epoxybutene. Biomonitoring methods need to be developed
for diepoxybutane and other putative reactive butadiene metabolites. With butadiene and related
compounds, the ultimate challenge is to identify useful biomarkers of exposure in which quantita-
tive linkages between exposure and internal dose of the important DNA-reactive metabolites are
established. Environ Health Perspect 104(Suppl 5):907-915 (1996)
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Introduction
Human epidemiological studies of butadi- compound and metabolites (e.g., epoxides);
ene can benefit from data on biomarkers of metabolites in excreta (e.g., mercapturic
I . I . I I . I I . I * this compound, particularly in the area of
biomarkers ofexposure. Biomonitoring of
exposure to butadiene and related air toxics
of low molecular weight could potentially
be based on chemical analysis of exhaled
breath, including parent chemical and
epoxide metabolites; blood levels ofparent
acids in urine); adducts ofreactive interme-
diates (e.g., epoxides) with DNA or blood
proteins; DNA adducts in urine; or analysis
ofa biological end point such as mutation
induction in specific genes (e.g., HPRT).
This article reviews the current knowledge
about biomarkers ofbutadiene, discusses the
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applicability ofbiomarkers in field studies
of this compound, and defines specific
research directions for expanded biomarker
use. Some ofthe advantages and limitations
in biomarker studies ofalkylating low-mol-
ecularweight agents are addressed.
1,3-Butadiene: Background
1,3-Butadiene is a flammable, colorless gas
with a mildly aromatic odor. The boiling
point of butadiene at 1 atmosphere is
-4.4°C, and the vapor pressure is 2100
mm Hg at 250C.
Butadiene is used in the production of
resins and plastics, including butadiene
rubber, styrene rubber, adiponitrile,
polychloroprene, nitrile rubber, styrene-
butadiene latex, and acrylonitrile-butadi-
ene-styrene (1). The butadiene used to
manufacture man-made rubber is primarily
for the production of automobile tires. In
1994, butadiene ranked in the top 20 of
synthetic organic chemicals produced in
the United States, with an annual produc-
tion over 3 billion pounds (2). Butadiene
is listed as one of 189 hazardous air pollu-
tants under the 1990 Clean Air Act
Amendments (3).
Sources of exposure to butadiene
include cigarette smoke and emissions from
butadiene production, storage, transport,
and end use. The most likely mode ofexpo-
sure to butadiene occurs in the industrial
setting or in the environment, where
inhalation ofbutadiene vapors is the route
ofuptake. Few data exist on concentrations
ofbutadiene in ambient air. Concentrations
of butadiene in urban air have been
reported to range from 1 to 10 ppb (4,5). A
mean concentration of 1.39 pg butadi-
ene/m3 (range 0.11-6.94 pg/m3 or 0.62
ppb, range 0.05-3.1 ppb) was reported for
24-hr ambient air samples taken in 19 U.S.
cities in 1987 to 1988 (6). Studies in
Sweden on urban air pollution show an
average level of0.3 ppb butadiene (7). The
U.S. Environmental Protection Agency
(U.S. EPA) estimated that butadiene is
emitted in automobile exhaust at 8.9 to 9.9
mg/mile (5.6-6.1 mg/km) and makes up
roughly 0.35% of total hydrocarbons in
exhaust emissions (8). Neligan (4) reported
a concentration ofbutadiene in automobile
exhaust of20 to 60 ppb. Lofroth et al. (9)
reported 0.4 mg butadiene/cigarette in
sidestream smoke, and levels in smoky
indoor environments were reported to range
from 10 to 20 pg/m3 (4.5-8.9 ppb).
Brunnemann et al. (10) reported an average
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amount of butadiene in sidestream ciga-
rette smoke of205 to 361 pg/cigarette and
16 to 75 pg/cigarette in mainstream
smoke. Typical occupational levels of
butadiene are less than 2 ppm (11).
The carcinogenicity of butadiene in
rodents is well established. Although both
sexes ofB6C3F1 mice and Sprague-Dawley
rats developed tumors in 2-year inhalation
rodent bioassays (12-14), the most strik-
ing aspect of butadiene-induced carcino-
genicity in rodents is the high sensitivity of
mice compared with rats. Rats developed
tumors from exposures to butadiene
concentrations (1000-8000 ppm) as much
as three orders of magnitude higher than
those that caused cancer in mice
(6.25-1250 ppm). Furthermore, tumor
sites differed in rats and mice. The carcino-
genicity data for rats and mice were used
for a butadiene risk assessment by the U.S.
Occupational Safety and Health
Administration (15). For the most part,
risk estimates ofcancer deaths for workers
exposed to 10 ppm butadiene were higher
when based on mouse tumor incidence
data compared to estimates derived from
rat tumor data.
The genotoxicity ofbutadiene has been
studied using a variety of in vitro and in
vivo mutagenicity assays [see review by de
Meester (16)]. For example, butadiene dis-
played mutagenic activity in bacteria
(Ames test), but only in the presence of
liver S9 fractions (17). Butadiene causes
genetic damage in bone marrow cells and
peripheral blood lymphocytes in B6C3F1
mice (18) but not in Sprague Dawley rats
(19,20), observations that correlate with
species differences in carcinogenicity.
The butadiene metabolites epoxy-
butene and diepoxybutane are also car-
cinogenic and genotoxic in vivo (21-25).
Diepoxybutane is a more potent carcino-
gen in mice than epoxybutene (21) and is
nearly 100 times more mutagenic on a
molar basis than epoxybutene in mam-
malian systems (26). Diepoxybutane also
induces genetic damage in vitro in
mammalian cells (Chinese hamster ovary
cells and human peripheral blood lympho-
cytes) at lower concentrations than
epoxybutene (27,28).
Metabolism of 1,3-Butadiene
Knowledge ofquantitative differences in
butadiene metabolism among species is
critical because metabolism is likely to be a
key factor for butadiene carcinogenicity.
Some pathways of butadiene metabolism
are illustrated in Figure 1. Three enzymes
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Figure 1. Some key pathways for butadiene metabolism. Ml: 1,2-dihydroxy-4-(N-acetylcysteinyl-S)butane; M2: 1-
hydroxy-2-(N-acetylcysteinyl-S)-3-butene.
appear to play major roles in the overall
metabolism of butadiene: cytochrome
P450 monooxygenase, epoxide hydrolase,
and glutathione (GSH) S-transferase. The
metabolic activation ofbutadiene proceeds
by cytochrome P450-mediated oxidation
to epoxybutene (29-33). Cytochrome
P4502E1 is the major P450 isozyme for
the metabolism of butadiene (32),
although P4502A6 can also oxidize butadi-
ene to epoxybutene (34). Epoxybutene is
metabolized further by cytochrome P450
to diepoxybutane, and recent studies indi-
cate that both P4502E1 and P4503A4 cat-
alyze this oxidation step (35). Epoxide
hydrolase and GSH S-transferase are the
two enzymes responsible for the metabolic
inactivation of epoxybutene (32,36-38)
and diepoxybutane (39,40).
Significant species differences exist in
metabolism of butadiene [reviewed in
Himmelstein et al. (41)]. Comparison of
butadiene metabolism in liver and lung
microsomes indicates that the rate ofmetab-
olism is greater in mice compared with rats
and humans (mice >>> rats _ humans)
(32). Additionally, mice have a faster rate of
GSH conjugation with epoxybutene in lung
tissues than rats or humans, and humans
have faster rates ofepoxybutene hydrolysis
by epoxide hydrolase compared to rats or
mice (32). The rate ofcytochrome P450-
mediated epoxidation of epoxybutene to
diepoxybutane in liver microsomes is high-
est in mice, while rats and humans have a
similar rate (35). Enzyme-mediated liver
GSH conjugation with diepoxybutane
indicates that the rate of conjugation is
greater in mice compared with rats and
humans (mice > rats > humans) (39).
Enzyme-mediated liver hydrolysis of
diepoxybutane indicates that the rate of
hydrolysis was greater in humans than in
mice and rats (humans>rats>mice) (40).
Numerous in vivo data substantiate the
in vitro metabolism studies showing that
butadiene undergoes oxidation to epoxy-
butene and that there are significant species
differences in metabolism [reviewed in
Himmelstein et al. (41)]. In studies by
Himmelstein et al. (42,43), peak concentra-
tions ofepoxybutene in mice compared to
those in rats were 4- to 8-fold higher in
blood, 13- to 15-fold higher in lung, and 5-
to 8-fold higher in liver following inhalation
of 62.5, 625, 1250, and 8000 (rats only)
ppm butadiene for up to 6 hr. The concen-
tration ofdiepoxybutane was greatest in the
lungs ofmice. Diepoxybutane could not be
detected in livers ofmice or lungs and livers
of rats. Thornton-Manning et al. (44)
recently reported that concentrations of
epoxybutene were 3 to 74 times greater in
tissues ofmice compared with rats follow-
ing exposure to 62.5 ppm butadiene for 4
hr. Levels ofdiepoxybutane in blood and
tissues of rats were 40- to 163-fold lower
than in corresponding mouse tissues.
1,3-Butadiene Biomarkers
UrinaryMetabolites
Osterman-Golkar et al. (45) investigated
the excretion ofepoxybutene mercapturic
acid in the urine ofWistar rats exposed to
butadiene concentrations of 0, 250, 500,
and 1000 ppm (6 hr/day, 5 days/week for
2 weeks). The samples were analyzed using
the method developed by Gerin and Tardif
(46) for the mercapturic acid ofethylene
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oxide. This method involves deacetylation
to give a cysteine adduct, derivatization
with phthaldialdehyde, and high-perfor-
mance liquid chromatography (HPLC)
with fluorescence detection. The product
analyzed in samples ofrat urine was identi-
cal to the main synthetic product of the
reaction between epoxybutene and cys-
teine. The authors assumed that the prod-
uct was S-(2-hydroxy-3-butenyl)cysteine;
however, the structure was not verified.
The urinary concentration of this product
increased proportionally with butadiene
exposure concentration; levels were about
6, 13, and 18 pmol/day for 250, 500, and
1000 ppm, respectively. Analysis of other
excretion products was not attempted. The
authors concluded that further improve-
ments are needed before the analytical
methods can be applied to biomonitoring
in humans (45).
Sabourin et al. (36) examined the
urinary excretion of mercapturic acids in
mice, rats, hamsters, and monkeys. All four
species produced two metabolites, 1,2-dihy-
droxy-4-(N-acetylcysteinyl-S)butane (Ml)
and 1-hydroxy-2-(N-acetylcysteinyl-S)-3-
butene (M2). M2 is formed by conjugation
of GSH with epoxybutene, and Ml
appears to be formed by GSH conjugation
with butenediol, the product ofhydrolysis
ofepoxybutene. When comparing the four
species, the ratio ofMl to the sum of M1
+ M2 was linearly related to hepatic epox-
ide hydrolase activities for each species.
Bechtold et al. (38) developed an assay
based on isotope-dilution gas chromatogra-
phy and mass spectrometry (GC-MS) for
the quantification of Ml and M2. The
assay was applied to urine samples of
employees at a butadiene production plant
and one outside control group that had no
known exposure to butadiene. This study
extended the findings of Sabourin et al.
(36) by showing that humans are similar
to the monkey in that M1 is the predomi-
nant metabolite in urine. The findings are
consistent with the higher ratio of
M1/(M1 + M2) in humans compared to
rats or mice and the higher rate ofepoxide
hydrolase activity in the livers of humans
compared to rats and mice (i.e., humans >
rats > mice) (32). The average values of
M1 for exposed, intermediately exposed,
nonexposed, and outside control employ-
ees were 3200 + 1600, 1390 ± 550, 630 ±
190, and 320 + 70 ng/ml (mean ± SE),
respectively. Exposed and intermediately
exposed employees were exposed to 3 to
4 ppm butadiene, while nonexposed and
outside control employees were exposed to
<0.1 ppm butadiene. Values for exposed
subjects were statistically different from the
outside control group (p= 0.05). MI was
also detected in urine of outside control
workers; the implications of this observa-
tion are unknown. The method of
Bechtold et al. (38), although limited to
assessment ofrecent exposure (the last day;
days since last exposure), is probably the
most sensitive method available at this time
to detect butadiene exposure in humans.
HemoglobinAdducts
The dose response for formation of
adducts of epoxybutene with N-terminal
valine in hemoglobin has been investigated
in butadiene-exposed mice and rats
(45,47,48) using the N-alkyl Edman
method (49) and GC-MS or GC and MS-
MS (tandem mass spectrometry) for
adduct determination. Male B6C3F1 mice
and Sprague-Dawley rats were exposed to
0, 2, 10, and 100 ppm butadiene
(6 hr/day, 5 days/week for 4 weeks) (47).
The adducts were detectable after 1 week
ofexposure at all butadiene exposure con-
centrations (unpublished observation). In
these studies, adduct levels in mice
increased linearly with butadiene concen-
tration. Adduct levels were about 3 to 8
times lower in rats than in mice, and the
levels in rats began to plateau above 10
ppm. Studies ofepoxybutene-hemoglobin
adducts in Wistar rats exposed to higher
butadiene concentrations (0, 250, 500, and
1000 ppm (6 hr/day, 5 days/week for 2
weeks) showed a proportional increase in
adduct levels with increasing exposure con-
centration (about 0.05 pmol/g globin per
ppmxhr). Albrecht et al. (48) exposed
mice and rats at 0, 50, 200, 500, and 1300
ppm and showed a nonlinear dose
response in mice at concentrations above
200 ppm and a linear dose response for
rats. The adduct data are in general
agreement with concentrations of epoxy-
butene measured in blood and tissues that
were lower in rats than in mice exposed to
butadiene (42-44,50). The low epoxy-
butene-hemoglobin adduct levels in rats
and mice suggest that some reactive
metabolite other than epoxybutene, pre-
sumably diepoxybutane, is the important
genotoxic metabolite.
According to studies in experimental
animals, the adducts ofepoxybutene with
N-terminal valine in hemoglobin are
chemically stable [shown for N-(2-
hydroxy-3-butenyl)valine [(45,50); and
unpublished data)]. This implies that
epoxybutene-hemoglobin adducts are
suitable for monitoringprolonged butadiene
exposures in humans.
Preliminary data on hemoglobin
adduct levels in nine workers at a U.S.
chemical production plant and a few out-
side controls were reported by Osterman-
Golkar et al. (47). The workers, all
nonsmokers, were divided into two groups
on the basis ofwork location. Exposures to
butadiene were estimated from an environ-
mental sampling survey conducted
between 3 and 9 months before the collec-
tion of blood samples. Increased adduct
levels (1.1-2.6 pmol/g globin; estimate of
adducts with both carbon 1 and carbon 2
of 1,2-epoxybutene) were recorded in
workers in the butadiene production areas
(n =4). Time-weighted average 8-hr area
samples showed a mean value ofabout 3.5
ppm, although most samples contained
< 1 ppm. Most ofthe samples with higher
levels were collected in areas not fre-
quented by workers, suggesting that the
average exposure ofworkers to butadiene
was < 3.5 ppm. As control groups, five
workers from two nonproduction areas-
the power plant (no exposure data avail-
able) and the central control area (about
0.03 ppm butadiene)-and two external
controls were evaluated. Adduct levels in
control samples were below the detection
limit of 0.5 pmol/g globin. The authors
noted that further research is needed to
more clearly define a relationship between
butadiene exposure and hemoglobin
adduct levels.
van Sittert and van Vliet (51)
compared the hemoglobin adduct level of
N-(2-hydroxy-3-butenyl)valine (formed by
reaction at carbon 1 of 1,2-epoxybutene)
in control and butadiene-exposed workers
at a manufacturing site that produces buta-
diene by a naptha cracking process.
Control workers were from the same plant
site but were not involved in butadiene
manufacturing. The median (range) adduct
levels were <2 (< 1 to <4) pmol/g globin in
nonsmoking (n= 17) and smoking subjects
(n= 9) exposed occupationally to butadi-
ene. Personal air samples taken during the
study were generally < 1 ppm (8-hr time-
weighted average). The median concentra-
tions of adducts were < 4 (< 1 to < 7)
pmol/g globin in nonsmoking control sub-
jects (n = 15) and <3 (< 2 to < 8) pmol/g
globin in smoking control subjects
(n = 10). The method detection limit for
N-(2-hydroxy-3-butenyl)valine was 1 to 8
pmol/g globin, indicating that these
adducts could not be detected in workers
exposed to < 1 ppm butadiene.
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Blood samples from 26 employees at a
butadiene manufacturing plant in Portugal
were analyzed for N-(2-hydroxy-3-
butenyl)valine using tandem mass spec-
trometry for adduct detection (52,53). The
subjects included smokers and nonsmok-
ers. Exposures to butadiene were estimated
from an environmental sampling survey
that was conducted in connection with the
biomonitoring study (54). The adduct lev-
els recorded in laboratory and maintenance
workers (<0.1 pmol/g globin; n=7; median
butadiene concentration 0.1 ppm) were not
increased above the background found in
the controls (< 0.13 pmol/g globin, n=9).
Increased adduct levels (on average, 0.16
pmol/g globin) were recorded in workers
engaged in butadiene sampling and voiding
in the butadiene production areas (n = 10;
median butadiene concentration, 1 ppm).
Mainstream smoke contains about 0.06
mg butadiene/cigarette (range 0.016-0.075
mg butadiene/cigarette) (10). The amount
of butadiene in the mainstream smoke of
30 cigarettes, about 1.8 mg, is similar to
the amount (-1.6 mg) that would be
inhaled during 8 hr ofwork at an air con-
centration of 0.1 ppm butadiene. Thus,
the contribution from smoking to the
adduct level in hemoglobin ofproduction
plant workers (reported cigarette consump-
tion 0-25 cigarettes/day) is expected to be
smaller than the contribution from expo-
sure to butadiene (median exposure level
about 1 ppm).
The most sensitive analytical tech-
niques used for adduct quantification are
based on cleavage of the adduct from the
protein chain (55). For low molecular
weight epoxides with intermediate to high
s-values (56) (e.g., ethylene oxide, epoxy-
butene, and styrene oxide), the N-terminal
valine in hemoglobin is an important bind-
ing site. Adducts with the N-terminal
amino acid can be released by a modified
Edman method (49) involving derivatiza-
tion with pentafluorophenyl isothio-
cyanate, extraction and purification ofthe
thiohydantoin (PFPTH) derivative of the
modified amino acid, and mass spectro-
metric quantification. For example, a
modified globin or peptide containing
adducts of deuterated ethylene oxide can
serve as an internal standard. The limit of
detection ofthe N-alkyl Edman method is
about 1 to 10 pmol/g globin using GC and
MS and about 0.05 to 1 pmol/g globin
using GC and MS-MS.
The analytical conditions are critical,
and different detection limits have been
achieved for the analysis of epoxybutene
adducts in different studies (47,51,52).
The method used by Osterman-Golkar et
al. (52) for adduct determination [derivati-
zation of large globin samples (200-300
mg) according to the N-alkyl Edman
method and detection of the alkylvaline-
PFPTH by GC and MS-MS] can be used
for monitoring ofexposure to butadiene at
the level ofparts per million or higher.
DNAAdducts andModifiedNudeic
Acid Bases in Urine
Methods being developed to monitor
DNA adducts of low molecular weight
compounds include immunological assays
(57), GC-MS (58,59), HPLC with elec-
trochemical detection (60) or fluorescence
detection (61), and the 32P-postlabeling
technique (62).
Peltonen et al. (63) investigated the
potential for using modified purine bases as
urinary markers ofbutadiene exposure. N-
7-(2-Hydroxy-3-buten-1-yl)guanine and
N-7-(1-hydroxy-3-buten-2-yl)guanine
were identified in calf thymus DNA incu-
bated with epoxybutene and in urine of
one worker exposed to butadiene. The
concentration of butadiene to which the
worker was exposed was not reported. The
authors used HPLC with electrochemical
detection; the limit ofdetection was 0.2 to
0.3 pmol guanine adduct. Further research
is needed to correlate guanine adducts in
urine with the exposure concentration of
butadiene.
Sorsa et al. (53) exposed Wistar rats
and CB6F, mice to 0, 50, 200, 500, and
1300 (mice only) ppm, 6 hr/day for 5 con-
secutive days. The 32P-postlabeling tech-
nique was used for analysis ofadenine-N6
adducts of epoxybutene. DNA was
digested to 3'-nucleotides; the adducts
were enriched by HPLC and were then
labeled. The labeled samples were purified
by thin-layer chromatography, and the final
analysis was based on HPLC with radioac-
tivity detection. The adduct levels in lung
samples of mice were slightly higher than
the adduct levels in rat lung. Adduct levels
in rat liver (about 2, 6, 18, and 26 fmol
adduct/100 nmol 3' dAMP for 0, 50, 200,
and 500 ppm, respectively) were about 10-
fold higher than in rat lungs. Adduct levels
in mouse liver were not analyzed. The
reported sensitivity ofthe assay was 200 to
500 attomol depending on the amount of
DNA used in the analysis.
BiologicalEndPoints
Three human population monitoring
studies for genotoxic end points in individ-
uals from butadiene production facilities
have been reported in the literature
(64-66). In a small pilot study at a butadi-
ene production facility (64), an increase in
hprt variant frequency (HPRT Vf) was
detected in workers in the high exposure
group (n = 8) compared to the low expo-
sure group (n= 5) and outside-facility con-
trols (n = 6). There was a correlation
between an increase in the HPRT Vf and
increased levels of a butadiene metabolite
(Ml) in urine. The HPRTVf assay, which
uses autoradiographic detection of hprt
variants, was used. Therefore, the increased
HPRT Vf cannot be confirmed as an
increased frequency ofin vivo HPRTmuta-
tion. Studies using the HPRT mutant T-
lymphocyte cloning assay combined with
T-cell receptor pattern and DNA sequence
analysis (67,68) are required to confirm the
observations ofWard et al. (64) on butadi-
ene-exposed human populations.
In a separate study, Au et al. (65)
reported no significant increase in chromo-
some aberrations in peripheral blood
lymphocytes isolated from the butadiene-
exposed group [individuals used for the Au
et al. (65) study were the same as those
reported in the Ward et al. (64) study].
Following in vitroX-ray irradiation oflym-
phocytes isolated from these individuals,
however, the number of induced chromo-
somal alterations in the butadiene-exposed
group was significantly increased relative to
controls. According to these researchers,
the increased frequency of chromosomal
alterations following X-ray irradiation in
the butadiene-exposed group may indicate
a DNA repair deficiency in the butadiene-
exposed population.
Peripheral blood lymphocytes from 40
exposed workers and 30 controls from two
butadiene production plants were evalu-
ated for chromosome damage (chromo-
some aberrations, micronuclei, and sister
chromatid exchange in peripheral lympho-
cytes) (66). The ambient exposure levels of
butadiene in the manufacturing plants
were in the range of 1 to 3 ppm. No expo-
sure-related increases in either of the cyto-
genetic end points assessed were observed
in the butadiene-exposed workers.
In Vivo StailityofAdducts
The accumulation of stable hemoglobin
adducts during prolonged exposure is the
result ofdaily increments (a) ofthe adduct
level, and daily losses due to removal ofthe
oldest fraction ofthe erythrocytes (1/ter; ter
is the erythrocyte lifespan) from circulation
(70-72). After exposure for a period of
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time exceeding ter (126 days in humans), a
steady-state adduct level (Ass) is attained:
Ass = ax ter/2=63 a
Thus, measurement ofAs. of stable
adducts gives information on exposure dur-
ing the months before blood sampling.
Unstable adducts build up to a less extent
and approach more rapidly the steady-state
level (71,72).
For a serum protein or DNA adduct,
the level approaches:
Ass=alk
where k includes constants for turnover of
the macromolecule and instability of the
adduct. Thus, the steady-state level of
chemically stable serum protein adducts is
approximately 30a (k'= 0.035 days) (73).
Several low molecular weight adducts
with N-terminal valine in hemoglobin,
including the adducts ofepoxybutene, eth-
ylene oxide (74), styrene oxide (75), and
acrylonitrile (76), have been studied in
experimental animals and appear to be
chemically stable at low exposure levels.
Tates (77) studied hydroxyethylvaline in
hemoglobin of four workers accidentally
exposed to high concentrations ofethylene
oxide. The adduct levels decreased linearly
over time and reached background values
after approximately 110 days, as expected
for chemically stable adducts.
Use ofadducts for dosimetry purposes
requires knowledge of the kinetics of
adduct elimination. Contrary to protein
adducts, DNA adducts are subjected to
repair, and their stability varies consider-
ably between type ofadduct and cell type.
In the absence of information on adduct
stability, DNA adduct measurements give
only qualitative information on exposure.
Comparison ofAdduct
Formation with 1,3-Butadiene
and Some Other Low
Molecular WeightCompounds
The daily adduct increment, a, given, for
example, in pmol adduct/g hemoglobin,
can be recalculated to adduct increment
per ppmxhr and used as a binding index
(HBI) for epoxybutene. This binding index
is directly proportional to the concentra-
tion in erythrocytes integrated over time
(AUC; area under the concentration curve)
ofthe adduct-forming reactive metabolite:
HBI=kHBxAUC
The constant, kHB, is the second-order rate
constant for adduct formation in hemoglo-
bin. kHB can be determined in in vitro
experiments and, accordingly, the relation-
ship between AUC and resulting adduct
levels can be established.
Table 1 presents data on hemoglobin
adduct levels from exposure to butadiene
and some related compounds (styrene, eth-
ylene, ethylene oxide, and acrylonitrile) in
nonsmokers, smokers, and subjects with
occupational exposure (52,53,78-82). The
HBI ofbutadiene, on the order of 1 x 10-3
pmol/g globin per ppmxhr, is low when
compared to the value calculated for rats
(50x 10-3), indicating a lower overall
efficiency of butadiene in humans than in
rats. However, the adducts measured are
those of the primary metabolite, epoxy-
butene. The HBI estimated for butadiene
is considerably lower than the HBI for
ethylene in humans.
Background Levels: A
Limitation and an Opportunity
The possibility of detecting chemical
exposures by adduct measurements is in
some cases limited by the presence ofhigh
background levels. This background may
be ofartifactual origin (i.e., introduced in
vitroduring handling ofthe blood sample).
Calleman et al. (83) analyzed cysteine
Table 1. Hemoglobin (N-terminal valine) adduct levels (pmol/g globin) from exposure to butadiene and some other low molecularweight compounds in referents (nonsmokers
and smokers) and subjects with occupational exposure.
Binding index
Compound Background adduct (pmol/g globin per
(reactive level (average, Exposure Adduct level ppm x hr unless Methodology and
intermediate) range, or mean ± SD) Type of exposure concentration (average, range) otherwise stated)a reference
Butadiene <0.13b Occupational GC/MS-MS (52,53)
(epoxybutene) Lab and maintenance work 0.1 (median value) <0.1b
Process work 1 ppm (median value) 0.16 <0.1-0.32b -0.5 x 10-3b.c
Styrene < lod Occupational 75 ppm (average) 28, 15-52 -1 x 10-3c GC/MS(78)
(styrene 7,8-oxide)
Ethylene 20, 12-27 (nonsmokers) Occupational 0.3 (0.1-1) ppm, 43, 22-65 0.2(0.6-0.06) GC/MS (79)
(ethylene oxide) 40 hr/week (nonsmokers)
16.1 ± 2.1 (nonsmokers) Tobacco smoking 1-25 cigarettes/day 146, 50-355 9 pmol/g globin GC/MS (80)
percigarette/day
63 ± 20 Tobacco smoking > 15 cigarettes/day 361 ± 107 (smoking GC/MS (81)
women; maternal blood)
42 ± 18 (newborn 147± 68 (newborn
babies' blood) babies' blood)
Ethylene oxide 14-26 (see also data Occupational Low-28 ppm/week 84-2070e ge GC/MS (82)
forethylene)
Acrylonitrilef < 2 Tobacco smoking 5-20 cigarettes/day 2.2-178 9 pmol/g globin GC/MS-MSf
percigarette/day
"Calculated assuming that the steady-state adduct level corresponds to exposure at work hours (8 hr/day, 5 days/week) during 9 weeks. bOnly one of the two regioisomers
measured. cOrder of magnitude. dCurrent unpublished studies indicate that the background is below 0.1 pmol/g globin. "Based on data from Duus et al. (82), we estimate a
steady-state adduct level of 3.4 nmol/g globin (Duus et al. (82) gives the value 2.4) for exposure to 1 ppm during work hours. fData from Bergmark(personal communication).
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adducts of ethylene oxide in globin
hydrolysates and found a high background
of hydroxyethylcysteine when mercap-
toethanol was added as an antioxidant dur-
ing the hydrolysis. Metabolic or catabolic
processes in blood samples in vitro may in
some cases be of concern in monitoring
studies because ofartifactual adduct forma-
tion. Tornqvist (84) demonstrated forma-
tion ofhydroxyethylvaline, possibly due to
ethylene production, during prolonged
storage ofsamples ofblood or erythrocytes.
Immediate precipitation and storage ofthe
globin eliminate this source oferror.
Background adducts may also originate
from confounding exposures to chemicals
that form the same adduct as the particular
compound studied, from additional
sources ofthis compound, or possibly from
incorporation of modified amino acids in
the biosynthesis ofhemoglobin. Examples
of compounds that may introduce the
hydroxyethyl adduct are ethylene and ethyl-
ene oxide, 1,2-dibromoethane, and
N-halogenoethyl-N-nitrosoureas. The
problem is still more pronounced for mer-
capturic acids. N-Acetyl-(2-hydroxyethyl)-
L-cysteine is a common urinary mercapturic
acid metabolite ofa large number ofstruc-
turally different chemicals, including acry-
lonitrile andvinyl chloride (85).
The study ofbackground blood protein
adducts may provide an opportunity to
identify cancer initiators of endogenous
origin or from widespread external sources
via their in vivoproducts ofreaction.
Detection of Low-level
Environmental Exposures
The possibility ofdetecting environmental
exposures by adduct measurements is
determined by the exposure level, the
binding index (Table 1), the analytical sen-
sitivity, the in vivo stability of the adduct,
Table 2. Estimates of hemoglobin adduct increments from exposures to ethylene, butadiene, styrene, or acryloni-
trile, at an air level of 10 ppb compared with background levels and increments from cigarette smoking (for refer-
ences, see Table 1).
Estimated Background Increment from
adduct increment in nonsmokers smoking (pmol/g globin
Compound (pmol/g globin) (pmol/g globin) Detection limita per cigarrette/day)
Ethylene 2 20 (mainly of -0.05 9
endogenous origin)
Butadiene 0.01b Low (<0.3) -0.05 Increment indicated in a
few heavy smokers
Styrene 0.01b Low(<0.1) -0.1 Not analyzed
Acrylonitrile 20c Low (<2) 2d 9
aGC/MS-MS. bCrude estimate from measurements at higher exposure levels, assuming a linear dose response.
cEstimate based on data for smoking. dAconsiderably lower limit could probably be achieved.
and the background adduct level in
nonexposed individuals. Which one of
these factors will set the limit depends, in
part, on the chemical. N-terminal valine
adduct increments from exposures to ethyl-
ene, butadiene, styrene, or acrylonitrile esti-
mated for an arbitrarily chosen air level of
10 ppb are presented in Table 2 and com-
pared to background levels and increments
from cigarette smoking. The adduct incre-
ments are based on binding indexes from
Table 1. The adducts are assumed to be
stable. The background level of adducts
(hydroxyethylvaline) from ethylene, about
20 pmol/g globin, corresponds to a tobacco
use of about two cigarettes per day and
hampers the detection and quantitation of
additional environmental, low-level sources
ofethylene. The background ofacrylonitrile
adducts (<2 pmol/g globin) corresponds to
less than one-quarter ofa cigarette per day.
The potential use ofthis adduct to quantify
exposure to environmental tobacco smoke
should be investigated. In the case ofbutadi-
ene and styrene, the background levels of
valine adducts are not known. The limiting
factors are the low binding levels ofthese
compounds and the sensitivity ofthe ana-
lytical methods. At present measurements
of hemoglobin adducts of styrene and
butadiene are limited to the montoring of
occupational exposures.
Future Research Opportunities
In summary, research on biomarkers of
exposure to butadiene is at the early stage
of development. Blood doses of the pri-
mary reactive metabolite, epoxybutene, can
be measured in globin samples ofhumans
with occupational exposure to butadiene
levels of about 1 ppm or higher. Recent
exposure to the same occupational expo-
sure levels can be detected by means of
mercapturic acids in the urine. Further
studies are required to determine the true
background levels ofthese biomarkers and
to evaluate the impact ofsmoking, both as
a source ofexposure to butadiene as well as
its possible influence on butadiene metabo-
lism. One of the key deficiencies of this
work relates to the complete absence of
biomarkers ofdiepoxybutane, an impor-
tant metabolite ofbutadiene. Metabolism,
toxicokinetic, and genotoxicity data clearly
indicate that diepoxybutane should be the
focus offurther biomarker research.
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